Sino Biopharm Wins NMPA Nod for Innovative Hepatitis B Drug Trial

Sino Biopharmaceutical ( (HK:1177) ) has issued an announcement.

Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has secured approval from China’s National Medical Products Administration to begin clinical trials of IM-101, a PreS1 recombinant fusion protein developed as a national Category 1 innovative drug for chronic hepatitis B. IM-101 is designed to break immune tolerance and restore HBV-specific immune responses, aiming for a functional cure by combining humoral and cellular mechanisms to neutralise viral particles, prevent reinfection and clear infected hepatocytes.

The company underscores that current hepatitis B treatments, such as nucleos(t) ide analogues and interferons, achieve low rates of functional cure and often require long-term therapy, highlighting the unmet need IM-101 seeks to address. The new candidate further strengthens Sino Biopharmaceutical’s liver disease pipeline, which includes late-stage assets like lanifibranor and TQA3605, Phase II agents targeting TLR-7 and THR, and a strategic collaboration with GSK on Bepirovirsen, positioning the group as a leading player in functional cure strategies for chronic hepatitis B and related liver conditions.

The most recent analyst rating on (HK:1177) stock is a Buy
with a HK$7.80 price target.
To see the full list of analyst forecasts on Sino Biopharmaceutical stock,
see the HK:1177 Stock Forecast page.